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ABSTRACT
Objectives: Outcomes of liver transplantations from
donation after circulatory death (DCD) donors may be
inferior to those achieved with donation after brain
death (DBD) donors. The impact of using DCD donors
is likely to depend on specific national practices.
We compared risk-adjusted graft loss and recipient
mortality after transplantation of DCD and DBD livers in
the UK.
Design: Prospective cohort study. Multivariable Cox
regression and propensity score matching were used to
estimate risk-adjusted HR.
Setting: 7 liver transplant centres in the National Health
Service (NHS) hospitals in England and Scotland.
Participants: Adults who received a first elective liver
transplant between January 2005 and December 2010
who were identified in the UK Liver Transplant Audit.
Interventions: Transplantation of DCD and DBD livers.
Outcomes: Graft loss and recipient mortality.
Results: In total, 2572 liver transplants were identified
with 352 (14%) from DCD donors. 3-year graft loss
(95% CI) was higher with DCD livers (27.3%, 21.8% to
33.9%) than with DBD livers (18.2%, 16.4% to 20.2%).
After adjustment with regression, HR for graft loss was
2.3 (1.7 to 3.0). Similarly, 3-year mortality was higher
with DCD livers (19.4%, 14.5% to 25.6%) than with DBD
livers (14.1%, 12.5% to 16.0%) with an adjusted HR of
2.0 (1.4 to 2.8). Propensity score matching gave similar
results. Centre-specific adjusted HRs for graft loss and
recipient mortality seemed to differ among transplant
centres, although statistical evidence is weak (p value for
interaction 0.08 and 0.24, respectively).
Conclusions: Graft loss and recipient mortality were
about twice as high with DCD livers as with DBD livers in
the UK. Outcomes after DCD liver transplantation may
vary between centres. These results should inform
policies for the use of DCD livers.
INTRODUCTION
The increasing disparity between the demand
and supply of donor livers is a major challenge.
The need to increase the donor pool, and
improve organ utilisation, has led to the
reintroduction and rapid expansion of the use
of livers from donation after circulatory death
(DCD) donors. These donors have been classi-
fied as either uncontrolled, where cardiac
arrest has occurred unexpectedly (Maastricht
categories I and II), or controlled, where
potential donors have life-sustaining treatment
withdrawn after further interventions are
deemed futile (Maastricht III), or circulatory
ARTICLE SUMMARY
Article focus
▪ There is increasing disparity between demand
and supply of donor livers for transplantation.
▪ The use of livers from donation after circulatory
death (DCD) donors—in addition to those from
donation after brain death (DBD)—increases the
donor pool.
▪ We compared graft loss and recipient mortality
after transplantation of DCD and DBD livers in
the UK.
Key messages
▪ Recipients of DCD livers, after risk adjustment,
have approximately twice the risk of graft loss
and death within 3 years of transplantation than
recipients of livers from DBD donors.
▪ The impact of using DCD livers on graft loss and
recipient mortality seemed to differ among the
seven UK transplant centres.
Strengths and limitations of this study
▪ A national database was used with near-complete
inclusion of all liver transplantations in the UK
with high data quality and follow-up, which elim-
inates the risk or selective reporting.
▪ Both multivariable regression analysis and pro-
pensity score matching were used to adjust for
differences risk factors for graft loss and patient
mortality between DBD and DCD donors and
recipients.
▪ We were not able to assess the impact that time
from withdrawal of life-sustaining treatment to
cardiac arrest has on post-transplant outcomes
of DCD livers.
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death occurs in a donation after brain death (DBD) donor
(Maastricht IV).1
Unlike DBD donors, livers from DCD donors undergo a
variable period of warm ischaemia, during which time irre-
versible cellular damage may occur. Reliably measuring
the warm ischaemic period is difficult outside of hospital,
which means that the use of livers from uncontrolled DCD
donors is limited.2 In contrast, planned withdrawal of life-
sustaining treatment in Maastricht III donors enables close
cardiorespiratory monitoring, provision of a prepared pro-
curement team and minimisation of subsequent warm
ischaemia. As such, the use of livers from controlled DCD
donors has risen dramatically in the USA3 and Europe.4
US registry analyses have demonstrated that DCD liver
transplantation has worse graft and patient survival than
DBD liver transplantation.5–9 This is thought to be pre-
dominantly due to a higher rate of biliary complications
in DCD livers than other causes of graft loss.10
Recognition of these issues has perhaps contributed to a
recent drop in the number of DCD livers transplanted
in the USA.3 11 However, as a result of encouraging early
reports12 and decreasing DBD liver transplantation rates,
the use of DCD livers in the UK is now more widespread
than in the USA.
As there are differences between UK and US practice
with respect to how DCD livers are being used,13 14 we
report in this article graft loss and recipient mortality
after transplantation of DCD and DBD livers in the UK.
Two risk-adjustment techniques were used to control for
differences in donor and recipient risk factors.
MATERIALS AND METHODS
Inclusion criteria
Using data submitted to the UK Liver Transplant Audit,15
we identified all adult patients (aged >16 years) receiving a
first liver transplant in the seven UK transplant centres
between 1 January 2005 and 31 December 2010. Follow-up
ceased on 31 March 2011. Regular checks indicate that
data are consistently more than 93% complete and accur-
ate.16–18 Patients receiving living or domino donors were
excluded, as were those having an emergency (‘super
urgent’19) or multiorgan transplant. We are not aware of
any uncontrolled DCD liver transplants having been per-
formed in the UK during the study period.
Donor and recipient selection and organ procurement
Criteria for DCD donor selection and acceptable post-
withdrawal haemodynamic parameters varied among the
liver transplant centres, but were broadly based on the
experience of Muiesan et al,12 and in line with US guide-
lines.19 Administration of heparin or vasodilators, or pre-
dissection of femoral vessels before death, is prohibited
by law in the UK. Death was declared after cardiorespira-
tory arrest with a minimum interval of 5 min. All UK
liver procurement centres used a super-rapid recovery
technique,19 although preservation fluid type, bag pres-
sure and the use of dual perfusion techniques varied.
Livers from DCD and DBD donors were allocated
locally, and centres chose recipients according to local
criteria.20 Optimal livers from DBD donors were offered
to paediatric centres for splitting and implantation of
the left lateral segment, with implantation of the
extended right lobe into an adult recipient.
Statistical analyses
Pearson’s χ2 test was used to identify differences of cat-
egorical variables and Student’s t test or Mann-Whitney
test for differences of continuous variables. Graft and
recipient survival after transplantation were estimated
using Kaplan-Meier methods. Graft loss was defined as
retransplantation or death, regardless of perceived graft
function at the time of death. Cold ischaemic time
(CIT) was defined as the duration from the start of cold
perfusion of the liver in the donor to organ removal
from ice immediately prior to implantation.
A multivariable Cox regression model was used to
adjust the comparisons of graft loss and recipient mor-
tality between DCD and DBD livers for differences in
risk factors at the time of transplantation. The donor,
recipient and operative characteristics presented in
tables 1 and 2 were included in the model. UK
End-Stage Liver Disease (UKELD) and Model for
End-Stage Liver Disease (MELD) scores were calculated
for recipients,21 22 but these scores were not incorpo-
rated in the multivariable model as the component vari-
ables of both were already included.
To test whether the impact of using DCD livers on
graft loss and patient mortality varied among UK trans-
plant centres, we included an interaction term of donor
type and centre in the Cox model. The likelihood ratio
test was used to test the statistical significance of the risk
factors. The results of the survival analyses are presented
as HR with 95% CI.
An analysis with propensity score matching was also
conducted. The propensity score is the probability that
a recipient would have received a liver from a DCD (as
opposed to DBD) donor, based on observed donor and
recipient characteristics. A logistic regression model
was used to generate the propensity score.23 Donor
type was regressed on main effects only and donor,
recipient and operative characteristics were selected
using a stepwise process with conservative removal
(p>0.20) and entry criteria (p<0.10). We considered all
two-way interactions of the main effects and explored
non-linear relationships by including quadratic terms
of continuous model factors. All interactions and quad-
ratic terms with a p value <0.05 were selected. We esti-
mated the propensity score based on the logistic
regression model as the sum of the products of the
model factors and their coefficients. Then, for each
recipient in the DCD group we selected an individual
from the DBD group by matching on the log of the
estimated propensity score, using a nearest-neighbour
matching algorithm with callipers (an interval) of
maximum width of 0.2 SDs. We compared the
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distribution of all model factors in the DCD and DBD
groups to assess the success of the propensity score
model. The above processes were repeated for each of
the 10 imputed data sets (see below for a description of
methods to deal with missing data). The balance in the
covariates across the treatment groups was considered
to be achieved if the standardised differences were less
than 10%.24 Cox regression was then performed on
each of the 10 sets of matched pairs to estimate the
effect of donor type on patient and graft survival. A
robust SE was used to allow for the clustering on the
pairs. The estimates were then combined using Rubin’s
rules to provide adjusted HRs and their 95% CI.
In addition to the donor, recipient and operative
characteristics presented in tables 1 and 2, we also con-
sidered the following characteristics as candidates for
inclusion in the propensity score model (all are yes/no
unless otherwise stated): lifestyle activity score on five-
point scale, liver failure grade (acute/not acute),
encephalopathy grade on five-point scale, oesophageal
varices, diuretic therapy, fever, sepsis, haemoglobin,
white cell count, platelet count, serum urea, anticyto-
megalovirus status and antihepatitis C virus status.
Types of biliary and hepatic arterial anastomoses were
also considered as was the use of antifibrinolytic
therapy.
Missing values
All model factors had missing values for less than 5% of
patients with the exception of donor history of diabetes
(7%) and donor organ appearance (19%). Multiple
imputation using chained equations was used to fill in
missing values. The imputation model included the
model factors above, type of donor as well as terms
representing the outcome (log of survival time and the
censoring indicator).25 We created 10 imputed data sets,
and the model parameters based on these data sets were
combined using Rubin’s rules.
RESULTS
We identified 2572 first elective adult liver transplants.
Of these, 352 (14%) had a graft from a DCD donor. Use
of livers from DCD donors progressively increased from
6.9% in 2005 to 26.3% in 2010, an almost four-fold rise
over that time period. Two centres used DCD donor
livers in more than 30% of first elective adult liver trans-
plants in 2010.
Donor, recipient and operative characteristics
Compared to DBD liver donors, DCD donors were
younger, had lower body mass indices, lower serum
sodium concentrations and were more likely to be men
(table 1). Although a similar proportion of organs
appeared normal in the two groups, DCD donors had a
higher proportion of missing values (29%) than DBD
donors (18%). The cause of death for DBD donors was
predominantly stroke (70%), whereas the corresponding
proportion in the DCD group was 49%. Trauma was
more common in DCD donors (23%) than in DBD
donors (11%). In 352 DCD donors, the median (IQR)
time from withdrawal of life support to cardiac arrest
was 15 (11–20) min, whereas the median duration from
cardiac arrest to cold perfusion was 12 (9–14) min.
Recipients of a DCD liver were more likely to be older,
men, have lower serum bilirubin concentration and
cancer as the primary liver disease (table 2). Both
UKELD and MELD scores were lower in recipients of
DCD livers, most probably because a higher proportion
of DCD recipients had cancer as their primary disease.
DCD livers were more likely to be used as whole rather
than partial grafts. Median graft CIT was significantly
lower for DCD livers and there were more ethnicity mis-
matches in this group.
Graft and patient survival
Graft loss was higher in DCD recipients (figure 1), with
a 3-year graft loss (95% CI) of 27.3% (21.8 to 33.9) for
Table 1 Donor characteristics by donor type
Liver donor type
DCD (n=352) DBD (n=2220) p Value Missing (n)Donor characteristics
Age, years 42 (16) 46 (15) <0.01 0
Male sex 206 (59) 1158 (52) 0.03 0
BMI, kg/m2 25 (4) 26 (7) <0.01 20
Serum sodium, mmol/L 144 (140–150) 147 (142–154) <0.01 4
Diabetes 14 (5) 111 (5) 0.93 154
Organ appearance
Healthy 176 (70) 1384 (76) 0.05 497
Suboptimal 75 (30) 440 (24)
Cause of death
Trauma 81 (23) 256 (12) <0.01 23
Stroke 173 (50) 1546 (70)
Anoxia 54 (16) 198 (9)
Other 37 (11) 204 (9)
Values are numbers (percentages) for categorical variables and means (SDs) or median (IQR) otherwise.
BMI, body mass index; DBD, donation after brain death; DCD, donation after circulatory death.
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DCD recipients and 18.2% (16.4 to 20.2) for DBD reci-
pients with an unadjusted HR of 1.6 (1.2 to 2.0; table 3).
Recipient mortality was also increased with DCD livers
(figure 1). Three-year mortality was 14.1% (12.5 to 16.0)
for DBD recipients and 19.4% (14.5 to 25.6) for DCD
recipients with an unadjusted mortality HR of 1.4 (1.1 to
2.0) for use of a DCD donor liver.
After adjustment using the multivariable Cox regres-
sion model, we found that the risk of graft loss within
3 years of transplantation in recipients of a DCD donor
liver was more than twice that of those receiving a DBD
liver: adjusted HR 2.3 (1.7 to 3.0). Adjusted 3-year
patient mortality was also significantly higher in recipi-
ents of livers from DCD donors: adjusted HR 2.0 (1.4 to
2.8; table 3).
After adjustment using the propensity score analysis,
use of a liver from a DCD donor was associated with an
adjusted HR of 2.3 (1.3 to 4.1) for graft loss. The
adjusted HR for recipient mortality was 2.0 (1.0 to 4.2;
table 3).
Centre-specific estimates of DCD risk
Although the interaction between donor type and
centre was not statistically significant for either graft loss
Table 2 Recipient and operative characteristics by donor type
Liver donor type
DCD (n=352) DBD (n=2220) p Value Missing (n)Recipient and operative characteristics
Age, years 53 (9) 52 (11) 0.02 0
Male sex 247 (70) 1436 (65) 0.04 0
BMI, kg/m2 27 (5) 27 (6) 0.94 12
Serum sodium, mmol/L 137 (134–140) 137 (134–140) 0.38 7
Serum potassium, mmol/L 4.2 (0.5) 4.2 (0.5) 0.23 52
Serum creatine, µmol/L 89 (72–109) 86 (72–104) 0.92 4
Serum albumin, g/L 32 (28–37) 32 (27–36) 0.40 14
Serum bilirubin, mmol/L 41(21–79) 47 (24–100) <0.01 8
INR 1.4 (1.2–1.6) 1.4 (1.2–1.6) 0.90 54
UKELD score 54 (50–57) 55 (51–59) <0.01 57
MELD score 15 (11–19) 15 (12–20) 0.04 57
Primary liver disease
Cancer 118 (33) 461 (21) <0.01 0
HCV 47 (13) 265 (12)
PSC 23 (7) 233 (10)
HBV 6 (2) 52 (2)
PBC 34 (10) 238 (11)
ALD 71 (20) 516 (23)
AID 22 (6) 193 (9)
Metabolic 15 (4) 86 (4)
Other 16 (5) 176 (8)
Previous abdominal surgery
No 315 (90) 1931 (87) 0.15 10
Yes 35 (10) 281 (13)
Inpatient and ventilatory status
Outpatient 313 (89) 1877 (85) 0.10 0
Inpatient, not ventilated 36 (10) 322 (14)
Ventilated 3 (1) 21 (1)
Days in intensive care 2 (1, 4) 2 (1, 4) 0.38 15
Preoperative renal support
No 333 (95) 2116 (96) 0.71 7
Yes 18 (5) 98 (4)
Organ type
Whole 343 (97) 1956 (88) <0.01 1
Partial 9 (3) 263 (12)
Cold ischaemic time, h 6.7 (5.6–8.0) 9.5 (7.8–11.1) <0.01 93
Anastomosis time, min 41 (35–50) 42 (36–51) 0.42 90
Ethnicity mismatch
No 272 (77) 1868 (84) <0.01 10
Yes 79 (22) 343 (15)
Values are numbers (percentages) for categorical variables and means (SDs) or median (IQR) otherwise.
AID, autoimmune disease; ALD, alcoholic liver disease; BMI, body mass index; DBD, donation after brain death; DCD, donation after
circulatory death; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalised ratio; MELD, Model for End-Stage Liver
Disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; UKELD, UK End-Stage Liver Disease.
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(p=0.08) or recipient mortality (p=0.24), the relative
impact of using DCD livers on graft loss and recipient
mortality seemed to vary among the seven transplant
centres. Centre-specific adjusted HRs for graft loss and
recipient mortality varied from being smaller than 1 to
larger than 4 (figure 2).
Figure 1 Graft survival after first
elective adult liver transplantation
using livers from donation after
circulatory death (DCD) donors
and donation after brain death
(DBD) donors.
Table 3 Recipient 3-year graft loss and mortality by donor type
Liver donor type
Unadjusted
HR (95% CI)
Adjusted
HR (95% CI)
Adjusted
HR (95% CI)
Multivariable model Propensity score analysis
Three-year graft loss percentage (95% CI)
Donation after circulatory death 27.3 (21.8 to 33.9) 1.6 (1.2 to 2.0) 2.3 (1.7 to 3.0) 2.3 (1.3 to 4.1)
Donation after brain death 18.2 (16.4 to 20.2) 1 1 1
Three-year mortality percentage (95% CI)
Donation after circulatory death 19.4 (14.5 to 25.6) 1.4 (1.1 to 2.0) 2.0 (1.4 to 2.8) 2.0 (1.0 to 4.2)
Donation after brain death 14.1 (12.5.to 16.0) 1 1 1
HRs are unadjusted or adjusted based on either a multivariable Cox regression model or propensity score matching.
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Causes of graft loss
When causes of graft loss were analysed over 3-year post-
transplantation, the rates of biliary causes of graft loss
were higher in livers from DCD donors (4/72 (6%))
than DBD donors (4/330 (1%; p=0.04). Rates of biliary
stricture requiring intervention were very similar
between the two groups (DCD donors 13/347 (4%) vs
DBD donors 81/2193 (4%; p=0.96)).
DISCUSSION
Recipients of DCD livers, after risk adjustment, have
approximately twice the risk of graft loss and death
within 3 years of transplantation than recipients of livers
from DBD donors. This is the first study that has ana-
lysed risk-adjusted outcomes in recipients of livers from
DCD donors outside of the USA. Although US-based
studies have reported on larger numbers of DCD liver
transplant recipients,6 7 9 13 rates of DCD liver usage in
the UK are more than double that of the USA.3 14
Our results are in contrast with single-centre reports
that demonstrate good short-term results with liver trans-
plantation from DCD donors,12 26 with graft loss and
patient mortality similar to those from DBD donors.27–29
However, it is important to note that we found that the
impact of using DCD livers on graft loss and recipient
mortality seemed to differ among the seven UK trans-
plant centres, although these differences did not reach
statistical significance. This finding indicates that it is
important to investigate centre-specific practices that
may impact on the outcomes of transplantation of DCD
livers, including the selection of DCD grafts, definition
of warm ischaemic limits and procurement and implant-
ation techniques.
Risk factors for graft loss and patient mortality are
unevenly distributed between DBD and DCD donors and
recipients. For example, partial organs were more often
used for DBD recipients than for DCD recipients.
However, risk adjustment or matching techniques30 are
therefore crucial for a valid comparison of outcomes.
Because estimates from multivariable models can be less
robust when many factors are included, we also used pro-
pensity score matching. Reassuringly, both risk-adjustment
techniques gave similar HRs for graft loss and recipient
death.
In the UK, DCD liver donors are marginally older and
have longer times from withdrawal of life-sustaining
treatment to cold perfusion than in the USA.6 7 9 13 14 31
These differences are likely to reflect a wider acceptance
of transplantation of DCD livers in the UK than in the
USA and that treatment withdrawal in the UK takes
place in the intensive care unit or the anaesthetic room
but not in theatre itself. However, CITs are shorter for
DCD livers in the UK, even taking into account differ-
ences in definitions between the two countries.6 7 13 32
This may be due to geographical differences between
the two countries (ie, longer distances between procur-
ing and implanting centres) or an increased willingness
on the part of UK surgeons to begin the recipient oper-
ation before the organ arrives at the implanting centre.
Transplanted livers from DCD donors appear particu-
larly susceptible to biliary complications, most commonly
ischaemic cholangiopathy, which is thought to occur as a
result of warm ischaemic damage to the biliary epithe-
lium sustained during the procurement process.10 33–36
We examined rates of graft loss from biliary causes and
found that this was a relatively rare cause of graft loss in
DCD as well as in DBD recipients. In addition, there was
no difference in the proportion of DCD and DBD reci-
pients who required an intervention for biliary strictures.
Although these findings concur with previous reports
suggesting that ischaemic cholangiopathy is not a major
problem in UK recipients of livers from DCD
donors,26 27 it should be recognised that analyses of
national registry data are prone to under-reporting of
postoperative complications.
Unfortunately, data on time from withdrawal of life-
sustaining treatment to cardiac arrest were missing in
more than 50% of DCD donors and therefore the
impact of this variable on outcome was not assessed.
Prolonged time from cardiac arrest to cold perfusion
has been shown to be a risk factor for the development
of ischaemic cholangiopathy35 and would therefore be
expected to lead to decreased graft survival. We found
no significant association (data not shown). This is again
likely to be due to lack of power or to most DCD donors
having similar times, with an IQR of just 5 h.
Defining acceptable warm ischaemic limits for livers
from DCD donors is hampered by the lack of data on
donor cardiorespiratory parameters after treatment with-
drawal. Some controlled DCD donors have prolonged
periods of cardiorespiratory stability before dying rapidly.
It is, therefore, possible that the duration of hypotension
or hypoxia has a greater impact on subsequent graft viabil-
ity than the duration from treatment withdrawal to cardiac
arrest or cold perfusion.8 37 National prospective data col-
lection of postwithdrawal cardiorespiratory parameters in
Maastricht III DCD donors has therefore been initiated in
both the UK and the USA.8 Further research is also
required into the impact of procurement techniques and
preservation fluids on graft function,38 and the emerging
role of machine perfusion.29
The allocation of deceased donor livers in the UK is
currently on a local basis, with national organ sharing
only for those patients with acute liver failure reaching
specific criteria.39 Although local allocation reduces CIT,
which is an important risk factor for graft survival, the
current system raises issues of equity of access to a
national resource. The ultimate aim of our analyses of
national data is to inform discussions on how best to
utilise this resource.40 For example, one could use our
results as further support for not using livers from DCD
donors for patients with a low risk of death on the
waiting list as these recipients are able to wait for a graft
that is more likely to have a favourable long-term
outcome. An exception could be made for patients with
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hepatocellular carcinoma. Although, these patients gen-
erally have low UKELD scores—indicating a low risk of
mortality on the waiting list—they have a high risk of
disease progression, which is an additional argument to
use livers from DCD donors for this group.
The relative benefit associated with transplantation of
a DCD versus a DBD donor liver is expected to be
dependent not only on donor and recipient factors, but
also on the overall availability of donor livers within each
region or country, the rate of deaths on the waiting list
and the impact of DCD transplantation on the subse-
quent need for retransplantation.41 Allocation policies
also need to determine whether DCD organs are to be
distributed on the basis of utility, urgency or overall sur-
vival benefit.42 Although livers transplanted from DCD
donors have inferior outcomes to those from DBD
donors, they remain a valuable additional source of
grafts, especially in countries with relatively low rates of
DBD organ donation.
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